Skip to main content
Robert Kirby, MD, Oncology, Plano, TX

RobertLewisKirbyMD

Oncology Plano, TX

Hematologic Oncology

Physician

Dr. Kirby is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kirby's full profile

Already have an account?

Education & Training

  • University of Kansas School of Medicine
    University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1980 - 1982
  • University of Kansas School of Medicine
    University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1979 - 1980
  • University of Kansas School of Medicine
    University of Kansas School of MedicineResidency, Internal Medicine, 1977 - 1979
  • University of Missouri-Columbia School of Medicine
    University of Missouri-Columbia School of MedicineClass of 1976

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1982 - 2025
  • KS State Medical License
    KS State Medical License 1977 - 2013
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Fellow American College of Physicians
  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
  • Super Doctor SuperDoctors.com

Publications & Presentations

PubMed

Journal Articles

  • Adjuvant Chemotherapy with Doxorubicin and Cyclophosphamide in Women with Rapidly Proliferating Node-Negative Breast Cancer  
    Jones, S., Clark, G., Kirby, R., et al, Clinical Breast Cancer Research, Vol 3, No. 2, 2002
  • Low Proliferation Rate of Invasive Node Negative Breast cancer Predicts for a Favorable Outcome Without Adjuvant Chemotherapy. Prospective evaluation of 669 Patients.  
    Jones, S., Clark,, Kolester, S., Kirby, R., et al., Clinical Breast Cancer Research, 6/2001
  • Randomized Double-Blind Prospective Trial to Evaluate the Effects of Sargramostim Versus Placebo in a Moderate Dose Flourouricil, Doxorubicin and Cyclophosphamide Adju...  
    Jones, S.E., Schottstaedt, M.W., Duncan, LA, Kirby R.L, et al, Journal of Clinical Oncology Vol 14, No. 11, 1997
  • Join now to see all

Abstracts/Posters

  • A Randomized, Double-Blind, Placebo Controlled Trial of P1XY321 After Moderate Dose FAC in Stage II and III Breast Cancer
    Jones,S., Khandelwal, p.,McIntyre, K.,Mennel, R., Orr, D., Kirby, R., et al, Proceedings of the American Society of Clinical Oncology, Abstract, 1997

Press Mentions

  • Cell Competition May Explain Cancer Relapses, Research Suggests
    Cell Competition May Explain Cancer Relapses, Research SuggestsNovember 7th, 2022
  • Tackling Resistance to HIF2 Drugs with an RNA-Based Therapy
    Tackling Resistance to HIF2 Drugs with an RNA-Based TherapyOctober 3rd, 2022
  • National Cancer Institute Renews $11.5 Million Program of Excellence Award in Kidney Cancer
    National Cancer Institute Renews $11.5 Million Program of Excellence Award in Kidney CancerSeptember 19th, 2022
  • Join now to see all

Committees

  • Member, Mary Crowley Research Center Institutional Review Board 2019 - 2024
  • Chairman 2015, Medical Center of Plano-Board of Trustees 2011 - 2015
  • Chairman, Medical City Plano Institutional Review Board 2009 - 2024

Professional Memberships